In Vivo Imaging of Brain Ischemia Using an Oxygen-Dependent Degradative Fusion Protein Probe

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Fujita, Youshi ^a   Kuchimaru, Takahiro ^b   Kadonosono, Tetsuya ^b   Tanaka, Shotaro ^c   Hase, Yoshiki ^a   Tomimoto, Hidekazu ^d   Hiraoka, Masahiro ^e   Kizaka Kondoh, Shinae ^b   Ihara, Masafumi ^a,f   Takahashi, Ryosuke ^a  

^a KYOTO UNIVERSITY   (Japan)

^b TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^d MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORESCENT DYE; HYBRID PROTEIN; HYPOXIA INDUCIBLE FACTOR 1; OXYGEN;

ALPHA CHAIN; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INJURY; BRAIN ISCHEMIA; DRUG DELIVERY SYSTEM; EARLY DIAGNOSIS; EX VIVO STUDY; FLUORESCENCE; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOLECULAR PROBE; MOUSE; NEUROIMAGING; NONHUMAN; PROTEIN DEGRADATION;

ANIMALS; BRAIN; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; HYPOXIA-ISCHEMIA, BRAIN; INFARCTION, MIDDLE CEREBRAL ARTERY; INJECTIONS, INTRAVENOUS; ISCHEMIC ATTACK, TRANSIENT; MALE; MICE; MICE, INBRED C57BL; MOLECULAR IMAGING; MOLECULAR PROBES; OXYGEN; RECOMBINANT FUSION PROTEINS;

EID: 84867688310     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048051     Document Type: Article

References (35)

1. Bergeron M, Yu AY, Solway KE, Semenza GL, Sharp FR, (1999) Induction of hypoxia-inducible factor-1 (HIF-1) and its target genes following focal ischemia in rat brain. Eur J Neurosci 11: 4159-4170.
2. Semenza GL, (2000) HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 88: 1474-1480.
3. Kaelin WG, (2005) Proline hydroxylation and gene expression. Annu Rev Biochem 74: 115-128.
4. Schofield CJ, Ratcliffe PJ, (2004) Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 5: 343-354.
5. Tanimoto K, Makino Y, Pereira T, Poellinger L, (2000) Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J 19: 4298-4309.
6. Marti HJ, Bernaudin M, Bellail A, Schoch H, Euler M, et al. (2000) Hypoxia-induced vascular endothelial growth factor expression precedes neovascularization after cerebral ischemia. Am J Pathol 156: 965-976.
7. Astrup J, Siesjo BK, Symon L, (1981) Thresholds in cerebral ischemia-the ischemic penumbra. Stroke 12: 723-725.
8. Sharp FR, Lu A, Tang Y, Millhorn DE, (2000) Multiple molecular penumbras after focal cerebral ischemia. J Cereb Blood Flow Metab 20: 1011-1032.
9. Bergeron M, Yu AY, Solway KE, Semenza GL, Sharp FR, (1999) Induction of hypoxia-inducible factor-1 (HIF-1) and its target genes following focal ischaemia in rat brain. Eur J Neurosci 11: 4159-4170.
10. Harada H, Kizaka-Kondoh S, Hiraoka M, (2006) Mechanism of hypoxia-specific cytotoxicity of procaspase-3 fused with a VHL-mediated protein destruction motif of HIF-1alpha containing Pro564. FEBS Lett 580: 5718-5722.
11. Harada H, Hiraoka M, Kizaka-Kondoh S, (2002) Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells. Cancer Res 62: 2013-2018.
12. Harada H, Kizaka-Kondoh S, Hiraoka M, (2005) Optical imaging of tumor hypoxia and evaluation of efficacy of a hypoxia-targeting drug in living animals. Mol Imaging 4: 182-193.
13. Harada H, Kizaka-Kondoh S, Li G, Itasaka S, Shibuya K, et al. (2007) Significance of HIF-1-active cells in angiogenesis and radioresistance. Oncogene 26: 7508-7516.
14. Hiraga T, Kizaka-Kondoh S, Hirota K, Hiraoka M, Yoneda T, (2007) Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res 67: 4157-4163.
15. Kizaka-Kondoh S, Itasaka S, Zeng L, Tanaka S, Zhao T, et al. (2009) Selective killing of hypoxia-inducible factor-1-active cells improves survival in a mouse model of invasive and metastatic pancreatic cancer. Clin Cancer Res 15: 3433-3441.
16. Kuchimaru T, Kadonosono T, Tanaka S, Ushiki T, Hiraoka M, et al. (2010) In vivo imaging of HIF-active tumors by an oxygen-dependent degradation protein probe with an interchangeable labeling system. PLoS ONE 5: e15736.
17. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF, (1999) In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285: 1569-1572.
18. Yuan F, Salehi HA, Boucher Y, Vasthare US, Tuma RF, et al. (1994) Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res 54: 4564-4568.
19. Shah ZA, Namiranian K, Klaus J, Kibler K, Doré S, (2006) Use of an optimized transient occlusion of the middle cerebral artery protocol for the mouse stroke model. J Stroke Cerebrovasc Dis 15: 133-138.
20. Chan DA, Sutphin PD, Yen SE, Giaccia AJ, (2005) Coordinate regulation of the oxygen-dependent degradation domains of hypoxia-inducible factor 1 alpha. Mol Cell Biol 25: 6415-6426.
21. Hase Y, Okamoto Y, Fujita Y, Kitamura A, Ito H, Maki T, et al. (2012) Cilostazol, a phosphodiesterase inhibitor, prevents no-reflow and hemorrhage in mice with focal cerebral ischemia. Exp Neurol 233: 523-533.
22. Cao G, Pei W, Ge H, Liang Q, Luo Y, et al. (2002) In vivo delivery of a Bcl-xL fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis. J Neurosci 22: 5423-5431.
23. Kilic E, Dietz GP, Hermann DM, Bahr M, (2002) Intravenous TAT-Bcl-Xl is protective after middle cerebral artery occlusion in mice. Ann Neurol 52: 617-622.
24. Kilic U, Kilic E, Dietz GP, Bahr M, (2003) Intravenous TAT-GDNF is protective after focal cerebral ischemia in mice. Stroke 34: 1304-1310.
25. Kim DW, Eum WS, Jang SH, Kim SY, Choi HS, et al. (2005) Transduced TAT-SOD fusion protein protects against ischemic brain injury. Mol Cells 19: 88-96.
26. Fisher M, Bastan B, (2008) Treating acute ischemic stroke. Curr Opin Drug Discov Devel 11: 626-632.
27. Savitz SI, Fisher M, (2007) Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials. Ann Neurol 61: 396-402.
28. Labiche LA, Grotta JC, (2004) Clinical trials for cytoprotection in stroke. NeuroRx 1: 46-70.
29. Schlaug G, Benfield A, Baird AE, Siewert B, Lövblad KO, et al. (1999) The ischemic penumbra: operationally defined by diffusion perfusion MRI. Neurology 53: 1528-1537.
30. Kucinski T, Naumann D, Knab R, Schoder V, Wegener S, et al. (2005) Tissue at risk is overestimated in perfusion-weighted imaging: MR imaging in acute stroke patients without vessel recanalization. Am J Neuroradiol 26: 815-819.
31. Nedergaard M, (1987) Neuronal injury in the infarct border: a neuropathological study in the rat. Acta Neuropathol 73: 267-274.
32. Kinouchi H, Sharp FR, Koistinaho J, Hicks K, Kamii H, et al. (1993) Induction of heat shock HSP70 mRNA and HSP70 kDa protein in neurons in the 'penumbra' following focal cerebral ischemia in the rat. Brain Res 619: 334-338.
33. Wang GL, Semenza GL, (1995) Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 270: 1230-1237.
34. Koistinaho J, Pasonen S, Yrjanheikki J, Chan PH, (1999) Spreading depression-induced gene expression is regulated by plasma glucose. Stroke 30: 114-119.
35. Gonzalez RG, (2006) Imaging-guided acute ischemic stroke therapy: From "time Is brain" to "physiology is brain". Am J Neuroradiol 27: 728-735.